Hintsa Tewoldemedhin, MD
Nephrology · Newark, OHNPI 1033168554
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,089 of the $2,594 with a category attached, or 80.5%. It is spread thinly across 25 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $696 and has fallen 51.7% since, to $337 in 2025.
Across 113 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$335
- OPKO Pharmaceuticals, LLC$260
- Ardelyx, Inc.$233
- AstraZeneca$183
- GSK$173
- ANI Pharmaceuticals, Inc.$161
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,08981%
- Education$50519%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 11 | $335 |
| OPKO Pharmaceuticals, LLC | 11 | $260 |
| Ardelyx, Inc. | 10 | $233 |
| AstraZeneca(2 entities) | 12 | $183 |
| GSK | 5 | $173 |
| ANI Pharmaceuticals, Inc. | 10 | $161 |
| Otsuka America Pharmaceutical, Inc. | 4 | $158 |
| Aurinia Pharma U.S., Inc. | 3 | $151 |
| Akebia Therapeutics Inc | 7 | $147 |
| Novo Nordisk | 5 | $122 |
| Bayer | 5 | $102 |
| Amgen | 5 | $101 |
| Novartis | 3 | $76 |
| Vifor Pharma, Inc. | 4 | $73 |
| Kyowa Kirin, Inc. | 3 | $61 |
| Sanofi | 3 | $57 |
| Boehringer Ingelheim | 2 | $44 |
| Lilly USA, LLC | 2 | $37 |
| Renalytix AI, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,594 in reported general payments places this provider in the 70th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 31 | $87,291 |
| Sevelamer Carbonate | 95 | $19,509 |
| Cinacalcet Hcl | 16 | $8,341 |
| Calcitriol | 322 | $5,647 |
| Calcium Acetate | 34 | $5,104 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,047 |
| Torsemide | 34 | $1,799 |
| Potassium Chloride | 45 | $1,732 |
| Midodrine Hcl | 21 | $1,364 |
| Furosemide | 154 | $930 |
| Amlodipine Besylate | 189 | $859 |
| Losartan Potassium | 82 | $616 |
| Lisinopril | 104 | $488 |
| Hydralazine Hcl | 40 | $477 |
| Carvedilol | 48 | $412 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Newark
- Brad RovinColumbus$379K
- Nissreen ElfadawyChardon$327K
- Andrew LazarBeachwood$315K
- Amit GovilCincinnati$298K
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Ibrahim AhmadKettering$232K
- Prabir Roy ChaudhuryCincinnati$205K
- Rupesh RainaAkron$163K
- Sevag DemirjianCleveland$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.